Eleven patients with "Covid-19" who have been in critical condition in New York and Houston hospitals since March 28 have undergone experimental treatment for the first time in the United States of America, after being approved urgently by the US Food and Drug Administration. The new treatment does not include any pharmaceutical preparations, but it is a plasma extracted from the blood of those recovering from Covid-19 infection. Researchers are now racing against time to judge its effectiveness for wider use.
According to the Dubai Future Foundation’s Future Observatory, the idea of using plasma depends on taking advantage of the antibodies that a person recovers after being infected with Covid-19, or other viruses, or having a specific vaccine to be associated with the virus and prevent it from causing disease. Its formation begins about one or two weeks after infection or vaccination, and its immune system keeps it in its memory for a long period that may last a lifetime, and it will be produced quickly if the person is exposed to the same infection in the future, and it is called active immunity.
There is another type of immunity called negative immunity, and it includes extracting antibodies from a recovered person and injecting them into the affected person's body, although this method has the advantage of providing them with instantaneous antibodies and not having to wait a week or two for the body to form them, but these antibodies continue in the body For a short period ranging from weeks to months, and does not give the person permanent immunity.
"We use plasma rich in antibodies extracted from the receptors to prevent another injury or treatment after an injury," said Jeffrey Henderson, an infectious and public pathologist at Washington University School of Medicine.
Extraction of antibodies from a recovered person from "Covid-19" and injecting them into an infected body.